alexa Abstract | Comparative Study of Efficacy between Pregabalin and Epalrestat in Diabetic Peripheral Neuropathic (Dpn) Pain

Asian Journal of Biomedical and Pharmaceutical Sciences
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Abstract

Diabetic neuropathies are a family of nerve disorders caused by diabetes. People with diabetes can, over time, develop nerve damage throughout the body. A total of fifty patients having diabetic neuropathic pain are recruited based on the inclusion and exclusion criteria. At first visit, patients are randomly assigned to one of the two treatment groups either Epalrestat or Pregabalin. Statistical analysis using student unpaired t-test. The scales used are Dallas pain questionnaire scale, Pain drawing scale, Lower extremity function scale; Biothesiometry score and plasma glucose post prandial. In the Dallas pain questionnaire scale, Pain drawing scale, Lower extremity function right and left toe scale in visit II and visit III are is P>0.05 significant value. In the Biothesiometry score right and left toe scale the ‘p’ value is <0.05, it has found that the reduction of diabetic neuropathy between two treatment groups during visit III is statistically differs. The plasma glucose post prandial the ‘p’ value is 0.0445 and it is <0.05, it has found that the reduction of PGPP between two treatment groups during visit II and III is statistically differs. The study concludes that there was rapid reduction of pain scores in pain rating scale; biothesiometry scores and reduction of PGPP levels are more in Pregabalin therapy when compared to Epalrestat therapy. The above information indicates that the efficacy observed for diabetic peripheral neuropathic pain relief, was more with Pregaballin therapy at a dose of 150 mg daily.

To read the full article Peer-reviewed Article PDF image

Author(s): Karunanithi P Madhavanmallayasamy Manikandan S Pandian PS Meera R

Keywords

Diabetic neuropathy, Epalrestat, Pregabalin, Dallas pain questionnaire

 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords